0001771917false00017719172024-02-222024-02-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): February 22, 2024 |
Karuna Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-38958 |
27-0605902 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
99 High Street, Floor 26 |
|
Boston, Massachusetts |
|
02110 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 857 449-2244 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Common stock, par value $0.0001 |
|
KRTX |
|
Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 22, 2024, Karuna Therapeutics, Inc. announced its financial results and general corporate updates for the fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
KARUNA THERAPEUTICS, INC. |
|
|
|
|
Date: |
February 22, 2024 |
By: |
/s/ Jason Brown |
|
|
|
Jason Brown
Chief Financial Officer |
Exhibit 99.1
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults under review with a Prescription Drug User Fee Act (PDUFA) action date of September 26, 2024
Results from the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia published in The Lancet
Announced appointments of Andrew Miller, Ph.D. as President of Research and Development and Mia Kelley, J.D. as General Counsel
Previously announced proposed acquisition of Karuna by Bristol Myers Squibb expected to close in the first half of 2024
$1.3 billion in cash, cash equivalents, and available-for-sale investment securities
BOSTON—February 22, 2024—Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update.
“2023 was a landmark year for Karuna, marked by the FDA acceptance of our NDA for KarXT for the treatment of schizophrenia in adults, with a potential launch in the second half of this year, and the continued advancement of our late-stage pipeline of KarXT as a potential adjunctive treatment for schizophrenia and in psychosis in Alzheimer’s disease,” said Bill Meury, president and chief executive officer of Karuna Therapeutics. “We look forward to continuing the work to bring KarXT and other potentially transformative medicines to patients living with serious mental illnesses, and we believe the pending acquisition of Karuna by Bristol Myers Squibb will accelerate our ability to achieve this mission.”
KEY PIPELINE HIGHLIGHTS
Karuna is advancing a pipeline of novel drug candidates for the treatment of various psychiatric and neurological conditions led by KarXT (xanomeline-trospium), an oral, investigational M1/M4-preferring muscarinic agonist.
KarXT
The NDA for KarXT for the treatment of schizophrenia in adults is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA action date of September 26, 2024. KarXT is also being evaluated in Phase 3 clinical trials as a potential adjunctive treatment for schizophrenia and as a potential treatment for psychosis in Alzheimer’s disease.
oThe NDA for KarXT for the treatment of schizophrenia in adults was accepted for review by the FDA in the fourth quarter of 2023 and assigned a PDUFA action date of September 26, 2024.
oResults from the EMERGENT-2 trial published in The Lancet in December 2023. The published manuscript, titled “Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial,” is available online, and appears in the January 13, 2024 print issue.
oAnnounced positive results from the Phase 1b Ambulatory Blood Pressure Monitoring trial in schizophrenia in the fourth quarter of 2023. Results from the trial demonstrate that KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia.
oPresented additional data from the EMERGENT program at the 2023 Neuroscience Education Institute (NEI) Congress and the CNS Summit in the fourth quarter of 2023. Poster presentations included new pooled efficacy and safety analyses across the three completed EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials, where:
▪KarXT demonstrated statistically significant and clinically meaningful improvements in symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) total score from baseline to week 5 compared to placebo (p<0.0001), the primary endpoint in the trials.
▪KarXT demonstrated statistically significant improvements across all secondary efficacy measures, including the PANSS positive subscale score (p<0.0001), PANSS negative subscale score (p<0.0001), PANSS Marder negative factor score (p<0.0001), and CGI-S score (p<0.0001).
▪KarXT was generally well tolerated, with common adverse reactions (>5% and at least twice placebo) being mostly cholinergic in nature, mild to moderate in severity, and transient over time. Further, KarXT was not associated with weight gain, adverse changes in metabolic parameters, or extrapyramidal symptoms.
oInterim long-term data from the EMERGENT-4 & 5 trials to be presented at upcoming medical congresses in the spring.
•Adjunctive treatment in schizophrenia
oTopline data from the Phase 3 ARISE trial evaluating the efficacy and safety of KarXT in schizophrenia when combined with a background antipsychotic is anticipated in 2025.
•Psychosis in Alzheimer’s disease
oTopline data from the Phase 3 ADEPT-1 and ADEPT-2 trials evaluating KarXT in psychosis in Alzheimer’s disease is anticipated in 2026.
Early-stage and discovery programs
The Karuna pipeline also includes clinical-stage candidate KAR-2618, a TRPC4/5 inhibitor for the treatment of mood and anxiety disorders, as well as pre-clinical muscarinic, TRPC4/5, and target-agnostic compounds for the treatment of psychiatric and neurological conditions.
•The Company is on track to initiate a Phase 1b trial of KAR-2618 in major depressive disorder (MDD) in 2024.
BUSINESS UPDATES
•Key leadership appointments. In January 2024, the Company appointed Andrew Miller, Ph.D. as President of Research and Development and Mia Kelley, J.D. as General Counsel. Dr. Miller succeeds Steve Paul, M.D., who continues to serve on the Company’s Board of Directors and was appointed as a member of the Company’s Scientific Advisory Board.
•Proposed acquisition of Karuna Therapeutics by Bristol Myers Squibb. In December 2023, Karuna and Bristol Myers Squibb announced they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The Boards of Directors of both companies have unanimously approved the transaction. The transaction is expected to close in the first half of 2024, subject to customary closing conditions, including approval of Karuna stockholders and receipt of required regulatory approvals.
ANTICIPATED UPCOMING MILESTONES
•Topline data from the Phase 3 EMERGENT-4 trial (2H 2024)
•Topline data from the Phase 3 EMERGENT-5 trial (2H 2024)
•KarXT in schizophrenia PDUFA action date (September 26, 2024)
•Launch of KarXT in schizophrenia, if approved (2H 2024)
•Initiation of the Phase 1b trial of KAR-2618 in major depressive disorder (2024)
•Topline data from the Phase 3 ARISE trial (2025)
•Topline data from the Phase 3 ADEPT-1 trial (2026)
•Topline data from the Phase 3 ADEPT-2 trial (2026)
FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
The Company reported a net loss of $113.8 million for the fourth quarter of 2023, and a net loss of $433.7 million for the year ended 2023, as compared to $76.2 million and $276.3 million for the prior year periods, respectively. The increase in net loss for the year was primarily attributable to higher operating expenses of $495.4 million compared to $300.3 million for the prior year period, driven by research and development expenses related to the Company’s ongoing KarXT clinical programs, NDA-supporting activities, pre-commercialization activities, the $15.0 million upfront license payment for Goldfinch Bio’s TRPC4/5 channel candidates, increased employee headcount across the organization, higher stock-based compensation, and expenses associated with the pending acquisition of Karuna by Bristol Myers Squibb.
Research and development expenses were $82.2 million for the fourth quarter of 2023, and $364.1 million for the year ended 2023, as compared to $66.0 million and $224.2 million for the prior year periods, respectively. The increase in research and development expenses for the year was primarily driven by expenses related to the Company’s KarXT clinical programs, NDA-supporting activities, the upfront license payment for Goldfinch Bio’s TRPC4/5 channel candidates, increased employee headcount, and higher stock-based compensation.
General and administrative expenses were $47.4 million for the fourth quarter of 2023, and $131.3 million for the year ended 2023, as compared to $24.3 million and $76.1 million for the prior year periods, respectively. The increase in general and administrative expenses for the year was primarily driven by the Company’s pre-commercialization activities, increased employee headcount, higher stock-based compensation, and expenses associated with the pending acquisition of Karuna by Bristol Myers Squibb.
The Company ended the year 2023 with $1.3 billion in cash, cash equivalents, and available-for-sale investment securities compared to $1.1 billion as of December 31, 2022. The increase was primarily the result of the completion of the Company’s follow-on public offering in March 2023, which resulted in net proceeds of $436.7 million.
About Karuna Therapeutics
Karuna Therapeutics is a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by serious mental illness. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples’ lives. For more information, please visit www.karunatx.com.
Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations about the timing of our ongoing and planned clinical trials and regulatory filings, our goals to develop and commercialize our product candidates, our liquidity and capital resources, the proposed acquisition of Karuna by Bristol Myers Squibb, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to obtain necessary funding, our ability to generate positive clinical trial results for our product candidates and other risks inherent in clinical development, the timing and scope of regulatory approvals, the proposed acquisition of Karuna by Bristol Myers Squibb, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, risks relating to business interruptions, and other risks set forth under the heading “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2023 and in our subsequent filings with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Karuna Therapeutics, Inc.
Unaudited Consolidated Statements of Operations
(in thousands, except share and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Year Ended |
|
|
|
December 31, |
|
|
December 31, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
License and other revenue |
|
$ |
— |
|
|
$ |
5,278 |
|
|
$ |
654 |
|
|
$ |
10,637 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
82,192 |
|
|
|
66,004 |
|
|
|
364,101 |
|
|
|
224,247 |
|
General and administrative |
|
|
47,394 |
|
|
|
24,310 |
|
|
|
131,330 |
|
|
|
76,066 |
|
Total operating expenses |
|
|
129,586 |
|
|
|
90,314 |
|
|
|
495,431 |
|
|
|
300,313 |
|
Loss from operations |
|
|
(129,586 |
) |
|
|
(85,036 |
) |
|
|
(494,777 |
) |
|
|
(289,676 |
) |
Other income, net: |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
16,285 |
|
|
|
9,567 |
|
|
|
61,179 |
|
|
|
14,178 |
|
Sublease income |
|
|
147 |
|
|
|
147 |
|
|
|
588 |
|
|
|
580 |
|
Total other income, net |
|
|
16,432 |
|
|
|
9,714 |
|
|
|
61,767 |
|
|
|
14,758 |
|
Net loss before income taxes |
|
|
(113,154 |
) |
|
|
(75,322 |
) |
|
|
(433,010 |
) |
|
|
(274,918 |
) |
Income tax provision |
|
|
(670 |
) |
|
|
(890 |
) |
|
|
(670 |
) |
|
|
(1,418 |
) |
Net loss attributable to common stockholders |
|
$ |
(113,824 |
) |
|
$ |
(76,212 |
) |
|
$ |
(433,680 |
) |
|
$ |
(276,336 |
) |
Net loss per share, basic and diluted |
|
$ |
(3.01 |
) |
|
$ |
(2.22 |
) |
|
$ |
(11.73 |
) |
|
$ |
(8.74 |
) |
Weighted average common shares
outstanding used in computing net loss per
share, basic and diluted |
|
|
37,780,998 |
|
|
|
34,406,182 |
|
|
|
36,959,049 |
|
|
|
31,629,013 |
|
Karuna Therapeutics, Inc.
Unaudited Consolidated Balance Sheet Data
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
December 31, 2023 |
|
|
December 31, 2022 |
|
Cash, cash equivalents and investments |
|
$ |
1,260,780 |
|
|
$ |
1,124,044 |
|
Working capital |
|
|
1,247,184 |
|
|
|
1,120,823 |
|
Total assets |
|
|
1,336,209 |
|
|
|
1,163,334 |
|
Total stockholders’ equity |
|
$ |
1,254,235 |
|
|
$ |
1,126,238 |
|
Investors:
Alexis Smith
+1 (617) 352-9917
asmith@karunatx.com
Media:
Julie Ciardiello
+1 (917) 647-0159
julie.ciardiello@karunatx.com
v3.24.0.1
Document And Entity Information
|
Feb. 22, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Feb. 22, 2024
|
| Entity Registrant Name |
Karuna Therapeutics, Inc.
|
| Entity Central Index Key |
0001771917
|
| Entity Emerging Growth Company |
false
|
| Entity File Number |
001-38958
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Tax Identification Number |
27-0605902
|
| Entity Address, Address Line One |
99 High Street, Floor 26
|
| Entity Address, City or Town |
Boston
|
| Entity Address, State or Province |
MA
|
| Entity Address, Postal Zip Code |
02110
|
| City Area Code |
857
|
| Local Phone Number |
449-2244
|
| Entity Information, Former Legal or Registered Name |
Not Applicable
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common stock, par value $0.0001
|
| Trading Symbol |
KRTX
|
| Security Exchange Name |
NASDAQ
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karuna Therapeutics (NASDAQ:KRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024
